Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at HC Wainwright lowered their Q1 2027 earnings per share (EPS) estimates for Nuvation Bio in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.34) per share.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 43.15%. The firm had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $34.39 million.

Several other brokerages have also recently issued reports on NUVB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, October 15th. Royal Bank Of Canada cut their target price on shares of Nuvation Bio from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday. JPMorgan Chase & Co. started coverage on shares of Nuvation Bio in a report on Tuesday, August 18th. They set an “overweight” rating and a $13.00 target price for the company. Citigroup restated a “market outperform” rating on shares of Nuvation Bio in a research report on Monday, October 19th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research report on Wednesday, September 16th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Nuvation Bio has a consensus rating of “Moderate Buy” and a consensus price target of $12.89.

Nuvation Bio Price Performance

Shares of NYSE NUVB opened at $4.26 on Friday. Nuvation Bio has a twelve month low of $4.05 and a twelve month high of $9.75. The company has a current ratio of 8.37, a quick ratio of 8.14 and a debt-to-equity ratio of 0.96. The firm has a 50-day moving average of $5.44 and a two-hundred day moving average of $5.38. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -10.64 and a beta of 1.73.

Insider Activity at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the completion of the sale, the insider directly owned 100,000 shares of the company’s stock, valued at $709,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 30.11% of the stock is currently owned by corporate insiders.

Institutional Trading of Nuvation Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Alps Advisors Inc. lifted its stake in Nuvation Bio by 32.2% during the third quarter. Alps Advisors Inc. now owns 465,179 shares of the company’s stock valued at $2,605,000 after buying an additional 113,184 shares in the last quarter. Torray Investment Partners LLC acquired a new position in shares of Nuvation Bio in the third quarter worth about $1,539,000. Profund Advisors LLC increased its position in shares of Nuvation Bio by 297.6% in the third quarter. Profund Advisors LLC now owns 240,483 shares of the company’s stock worth $1,347,000 after acquiring an additional 179,994 shares in the last quarter. Sterling Capital Management LLC increased its position in shares of Nuvation Bio by 847.9% in the third quarter. Sterling Capital Management LLC now owns 8,389 shares of the company’s stock worth $47,000 after acquiring an additional 7,504 shares in the last quarter. Finally, GK Wealth Management LLC acquired a new stake in shares of Nuvation Bio during the third quarter valued at approximately $52,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio News Roundup

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: IBTROZI generated $27.5 million in Q3 net product revenue, and the company reported $45.0 million in total revenue, ahead of the cited $34.39 million analyst estimate. Management said IBTROZI grew 18% sequentially and leads the ROS1 market in new patient starts and active patients. Nuvation Bio Q3 results and business update
• Positive Sentiment: The company outlined potential European approval for IBTROZI in the first half of next year, which could trigger an approximately $30 million milestone payment. Europe approval and milestone update
• Positive Sentiment: Further pipeline and product catalysts include an FDA label update reflecting a 49.7-month median duration of response for IBTROZI in the specified patient group, Fast Track designation for safusidenib, and $663.4 million in cash, equivalents, and marketable securities at quarter-end. Nuvation Bio Q3 results and business update
• Negative Sentiment: Royal Bank of Canada lowered its price target from $20 to $17, while maintaining an Outperform rating. B. Riley also cut its target, from $14 to $13, but kept its Buy rating. Target reductions may weigh on sentiment even though both firms remain positive on the shares. Royal Bank of Canada rating update B. Riley price target update
• Negative Sentiment: NUVB reported a Q3 loss of $0.12 per share. That matched the consensus cited by some reports but was a penny worse than the $0.11 loss estimate cited by Zacks, making the earnings picture slightly mixed despite the revenue beat. Zacks Q3 earnings report

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.